Interpatient variability in IMPDH activity in MMF-treated renal transplant patients is correlated with IMPDH type II 3757T>C polymorphism

Pharmacogenetics and Genomics

Volumn 19, Issue 8, 2009, Pages 626-634

  Sombogaard, Ferdi ^a   Van Schaik, Ron H N ^a   Mathot, Ron A ^a   Budde, Klemens ^b   Van Der Werf, Marloes ^a   Vulto, Arnold G ^a   Weimar, Willem ^a   Glander, Petra ^b   Essioux, Laurent ^c   Van Gelder, Teun ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

^b CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^c Department of Pharmacogenetics F Hoffmann La Roche ^*  (Switzerland)

Author keywords

Inosine monophosphate dehydrogenase inhibitor; Kidney transplantation; Mycophenolate mofetil; Pharmacodynamics; Single nucleotide polymorphism

Indexed keywords

ADENOSINE KINASE; FK; INOSINATE DEHYDROGENASE; INOSINE MONOPHOSPHATE DEHYDROGENASE TYPE II; MMF; MYCOPHENOLIC ACID; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OXIDOREDUCTASE; PREDNISONE; TACROLIMUS; THYMOCYTE ANTIBODY; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; COHORT ANALYSIS; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG BLOOD LEVEL; ENZYME ACTIVITY; FEMALE; GENE EXPRESSION; GENE FREQUENCY; GENETIC DIFFERENCE; GENETIC VARIABILITY; GRAFT RECIPIENT; GRAFT REJECTION; HETEROZYGOSITY; HETEROZYGOTE; HOMOZYGOSITY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; WILD TYPE;

ADULT; AREA UNDER CURVE; COHORT STUDIES; FEMALE; GENETIC VARIATION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; IMP DEHYDROGENASE; KIDNEY FAILURE, CHRONIC; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; MYCOPHENOLIC ACID; PHARMACOGENETICS; POLYMORPHISM, SINGLE NUCLEOTIDE; PROSPECTIVE STUDIES; TREATMENT OUTCOME;

EID: 68849093870     PISSN: 17446872     EISSN: 17446880     Source Type: Journal    
DOI: 10.1097/FPC.0b013e32832f5f1b     Document Type: Article

References (43)

1. Kaufman DB, Shapiro R, Lucey MR, Cherikh WS, Bustami T, Dyke DB. Immunosuppression: practice and trends. Am J Transplant 2004;4(S9):38-53.
2. Van Gelder T. Mycophenolate mofetil: how to further improve using an already successful drug? Am J Transplant 2005; 5:199-200.
3. Van Gelder T, Hilbrands LB, Vanrenterghem Y, Weimar W, de Fijter JW, Squifflet JP, et al. A randomized double-blind, multicenter plasma concentration controlled study of the safety and efficacy of oral mycophenolate mofetil for the prevention of acute rejection after kidney transplantation. Transplantation 1999; 68:261-266.
4. Le Meur Y, Buchler M, Thierry A, Caillard S, Villemain F, Lavaud S, et al. Individualized mycophenolate mofetil dosing based on drug exposure significantly improves patient outcomes after renal transplantation.
5. Am J Transplant 2007; 7:2496-2503.
6. Shaw LM, Korecka M, Venkataramanan R, Goldberg L, Bloom R, Brayman KL. Mycophenolic acid pharmacodynamics and pharmacokinetics provide a basis for rational monitoring strategies. Am J Transplant 2003; 3:534-542.
7. Glander P, Hambach P, Braun KP, Fritsche L, Waiser J, Mai I, et al. Effect of mycophenolate mofetil on IMP dehydrogenase after the first dose and after long-term treatment in renal transplant recipients. Int J Clin Pharmacol Ther 2003; 41:470-476.
8. Klupp J, Holt DW, van Gelder T. How pharmacokinetic and pharmacodynamic drug monitoring can improve outcome in solid organ transplant recipients. Transpl Immunol 2002; 9:211-214.
9. Langman U, Shapiro AM, Lakey JR, LeGatt DF, Kneteman NM, Yatscoff RW. Pharmacodynamic assessment of mycophenolic acid-induced immunosuppression by measurement of inosine monophosphate dehydrogenase activity in a canine model. Transplantation 1996; 61:87-92.
10. Futer O, Sintchak MD, Caron PR, Nimmesgern E, DeCenzo MT, Livingston DJ, et al. A mutational analysis of the active site of human type II inosine 5′-monophosphate dehydrogenase. Biochim Biophys Acta 2002; 1594:27-39.
11. Natsumeda Y, Ohno S, Kawasaki H, Konno Y, Weber G, Suzuki K. Two distinct cDNAs for human IMP dehydrogenase. J Biol Chem 1990; 265:5292-5295.
12. Carr SF, Papp E, Wu JC, Natsumeda Y Characterization of human type I and type II IMP dehydrogenases. J Biol Chem 1993; 268:27286-27290.
13. Jain J, Almquist SJ, Ford PJ, Shlyakhter D, Wang Y, Nimmesgern E, et al. Regulation of inosine monophosphate dehydrogenase type I and type II isoforms in human lymphocytes. Biochem Pharmacol 2004; 67:767-776.
14. Farazi T, Leichman J, Harris T, Cahoon M, Hedstrom L. Isolation and characterization of mycophenolic acid-resistant mutants of inosine-5′- monophosphate dehydrogenase. J Biol Chem 1997; 272:961-965.
15. Natsumeda Y, Carr SF. Human type I and II IMP dehydrogenases as drug targets. Ann N Y Acad Sci 1993; 696:88-93.
16. Hager PW, Collart FR, Huberman E, Mitchell BS. Recombinant human inosine monophosphate dehydrogenase type I and type II proteins. Purification and characterization of inhibitor binding. Biochem Pharmacol 1995;49:1323-1329.
17. Weigel G, Griesmacher A, Zuckermann AO, Laufer G, Mueller MM. Effect of mycophenolate mofetil therapy on inosine monophosphate dehydrogenase induction in red blood cells of heart transplant recipients. Clin Pharmacol Ther 2001; 69:137-144.
18. Vethe NT, Mandla R, Line PD, Midtvedt K, Hartmann A, Bergan S. Inosine monophosphate dehydrogenase activity in renal allograft recipients during mycophenolate treatment. Scand J Clin Lab Invest 2006; 66:31-44.
19. Sanquer S, Breil M, Baron C, Dhamane D, Astier A, Lang P. Induction of inosine monophosphate dehydrogenase activity after long-term treatment with mycophenolate mofetil. Clin Pharmacol Ther 1999; 65:640-648.
20. Vannozzi F, Filipponi F, Di PA, Danesi R, Urbani L, Bocci G, et al. An exploratory study on pharmacogenetics of inosine-monophosphate dehydrogenase II in peripheral mononuclear cells from liver-transplant recipients. Transplant Proc 2004; 36:2787-2790.
21. Goldsmith D, Carrey EA, Edbury S, Smolenski RT, Jagodzinski P, Simmonds HA. Mycophenolate mofetil, an inhibitor of inosine monophosphate dehydrogenase, causes a paradoxical elevation of GTP in erythrocytes of renal transplant patients. Clin Sci (Lond) 2004; 107:63-68.
22. Bremer S, Rootwelt H, Bergan S. Real-time PCR determination of IMPDH1 and IMPDH2 expression in blood cells. Clin Chem 2007; 53:1023-1029.
23. Bremer S, Mandla R, Vethe NT, Rasmussen I, Rootwelt H, Line PD, et al. Expression of IMPDH1 and IMPDH2 after transplantation and initiation of immunosuppression. Transplantation 2008; 85:55-61.
24. Glander P, Braun KP, Hambach P, Bauer S, Mai I, Roots I, et al. Non-radioactive determination of inosine 5′-monophosphate dehydro-genase (IMPDH) in peripheral mononuclear cells. Clin Biochem 2001; 34:543-549.
25. Budde K, Glander P, Bauer S, Braun K, Waiser J, Fritsche L, et al. Pharmacodynamic monitoring of mycophenolate mofetil. Clin Chem Lab Med 2000; 38:1213-1216.
26. Budde K, Glander P, Kramer BK, Fischer W, Hoffmann U, Bauer S, et al. Conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium in maintenance renal transplant recipients receiving tacrolimus: clinical, pharmacokinetic, and pharmacodynamic outcomes. Transplantation 2007; 83:417-424.
27. Glander P, Hambach P, Braun KP, Fritsche L, Giessing M, Mai I, et al. Pre-transplant inosine monophosphate dehydrogenase activity is associated with clinical outcome after renal transplantation. Am J Transplant 2004; 4:2045-2051.
28. Burckart GJ, Liu XI. Pharmacogenetics in transplant patients: can it predict pharmacokinetics and pharmacodynamics? Ther Drug Monit 2006; 28:23-30.
29. Aherne A, Kennan A, Kenna PF, McNally N, Lloyd DG, Alberts IL, et al. On the molecular pathology of neurodegeneration in IMPDH1-based retinitis pigmentosa. Hum Mol Genet 2004; 13:641-650.
30. Bowne SJ, Sullivan LS, Mortimer SE, Hedstrom L, Zhu J, Spellicy CJ, et al. Spectrum and frequency of mutations in IMPDH1 associated with autosomal dominant retinitis pigmentosa and leber congenital amaurosis. Invest Ophthalmol Vis Sci 2006; 47:34-42.
31. Bowne SJ, Liu Q, Sullivan LS, Zhu J, Spellicy CJ, Rickman CB, et al. Why do mutations in the ubiquitously expressed housekeeping gene IMPDH1 cause retina-specific photoreceptor degeneration? Invest Ophthalmol Vis Sci 2006; 47:3754-3765.
32. Mortimer SE, Hedstrom L. Autosomal dominant retinitis pigmentosa mutations in inosine 5′-monophosphate dehydrogenase type I disrupt nucleic acid binding. Biochem J 2005; 390:41-47.
33. Wang J, Yang JW, Zeevi A, Webber SA, Girnita DM, Selby R, et al. IMPDH1 gene polymorphisms and association with acute rejection in renal transplant patients. Clin Pharmacol Ther 2008; 83:711-717.
34. Wang J, Zeevi A, Webber S, Girnita DM, Addonizio L, Selby R, et al. A novel variant L263F in human inosine 5′-monophosphate dehydrogenase 2 is associated with diminished enzyme activity. Pharmacogenet Genomics 2007; 17:283-290.
35. Streit F, Shipkova M, Armstrong VW, Oellerich M. Validation of a rapid and sensitive liquid chromatography-tandem mass spectrometry method for free and total mycophenolic acid. Clin Chem 2004; 50:152-159.
36. Brandhorst G, Streit F, Goetze S, Oellerich M, Armstrong VW. Quantification by liquid chromatography tandem mass spectrometry of mycophenolic acid and its phenol and acyl glucuronide metabolites. Clin Chem 2006; 52:1962-1964.
37. Glander P, Sombogaard F, Budde K, van Gelder T, Hambach P, Liefeldt L, et al. Improved assay for the non-radioactive determination of inosine 5′-monophosphate dehydrogenase (IMPDH) activity in peripheral blood mononuclear cells (PBMCs). Ther Drug Monit 2009; 31:351-359.
38. Grinyo J, Vanrenterghem Y, Nashan B, Vincenti F, Ekberg H, Lindpaintner K, et al. Association of four DNA polymorphisms with acute rejection after kidney transplantation. Transpl Int 2008; 21:879-891.
39. Shaw LM, Nicholls A, Hale M, Armstrong VW, Oellerich M, Yatscoff R, et al. Therapeutic monitoring of mycophenolic acid. A consensus panel report. Clin Biochem 1998; 31:317-322.
40. Shaw LM, Holt DW, Oellerich M, Meiser B, Van Gelder T. Current issues in therapeutic drug monitoring of mycophenolic acid: report of a roundtable discussion. Ther Drug Monit 2001; 23:305-315.
41. Budde K, Braun KP, Glander P, Bohler T, Hambach P, Fritsche L, et al. Pharmacodynamic monitoring of mycophenolate mofetil in stable renal allograft recipients. Transplant Proc 2002; 34:1748-1750.
42. Farrall M. Quantitative genetic variation: a post-modern view. Hum Mol Genet 2004; 13 (Review Issue 1):R1-R7.
43. Xie HG, Wood AJ, Kim RB, Stein CM, Wilkinson GR. Genetic variability in CYP3A5 and its possible consequences. Pharmacogenomics 2004; 5:243-272.